The systemic immune-inflammation index is superior to predicting clinical remission and relapse for ulcerative colitis patients treated with vedolizumab

The systemic immune-inflammation index is superior to predicting clinical remission and relapse for ulcerative colitis patients treated with vedolizumab

BackgroundVedolizumab (VDZ), a novel biologic targeting α4β7 integrin, is safe and effective for the treatment of patients with ulcerative colitis (UC). The objective of this study was to compare the potential of the Platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), and syste...

Full description

Saved in:
Bibliographic Details
Main Authors: Jing Yan, Jun Wu, Rongkun Wang, Pin Meng, Ailing Liu, Yonghong Xu
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-03-01
Series:Frontiers in Medicine
Subjects:
ulcerative colitis
vedolizumab
biomarkers
systemic immuneinflammation index
prognosis
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2025.1524307/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items